Media stories about Biodel (NASDAQ:ALBO) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biodel earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.3698240781073 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several research analysts recently issued reports on ALBO shares. Zacks Investment Research cut shares of Biodel from a “hold” rating to a “sell” rating in a report on Tuesday, May 23rd. Wedbush started coverage on shares of Biodel in a report on Friday, June 30th. They set an “outperform” rating for the company. Needham & Company LLC started coverage on shares of Biodel in a report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price target for the company. Finally, Cowen and Company started coverage on shares of Biodel in a report on Wednesday, August 16th. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $40.33.
Biodel (ALBO) opened at 23.32 on Wednesday. Biodel has a one year low of $11.70 and a one year high of $37.69. The firm has a 50-day moving average of $23.88 and a 200-day moving average of $22.55. The stock’s market capitalization is $207.13 million.
Biodel (NASDAQ:ALBO) last posted its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). On average, equities research analysts forecast that Biodel will post ($3.64) earnings per share for the current year.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.